DeepSynergy: predicting anti-cancer drug synergy with Deep Learning. by Preuer, Kristina et al.
Data and text mining
DeepSynergy: predicting anti-cancer drug
synergy with Deep Learning
Kristina Preuer1, Richard P. I. Lewis2, Sepp Hochreiter1, Andreas Bender2,
Krishna C. Bulusu2,3 and Gu¨nter Klambauer1,*
1Institute of Bioinformatics, Johannes Kepler University, 4040 Linz, Austria, 2Department of Chemistry, Centre for
Molecular Science Informatics, University of Cambridge, Cambridge CB2 1EW, UK and 3Oncology Innovative
Medicines and Early Development, AstraZeneca, Hodgkin Building, Chesterford Research Campus, Saffron
Walden, Cambs CB10 1XL, UK
*To whom correspondence should be addressed.
Associate Editor: Jonathan Wren
Received on August 9, 2017; revised on December 6, 2017; editorial decision on December 8, 2017; accepted on December 14, 2017
Abstract
Motivation: While drug combination therapies are a well-established concept in cancer treatment,
identifying novel synergistic combinations is challenging due to the size of combinatorial space.
However, computational approaches have emerged as a time- and cost-efficient way to prioritize
combinations to test, based on recently available large-scale combination screening data.
Recently, Deep Learning has had an impact in many research areas by achieving new state-of-the-
art model performance. However, Deep Learning has not yet been applied to drug synergy predic-
tion, which is the approach we present here, termed DeepSynergy. DeepSynergy uses chemical
and genomic information as input information, a normalization strategy to account for input data
heterogeneity, and conical layers to model drug synergies.
Results: DeepSynergy was compared to other machine learning methods such as Gradient
Boosting Machines, Random Forests, Support Vector Machines and Elastic Nets on the largest
publicly available synergy dataset with respect to mean squared error. DeepSynergy significantly
outperformed the other methods with an improvement of 7.2% over the second best method at
the prediction of novel drug combinations within the space of explored drugs and cell lines. At
this task, the mean Pearson correlation coefficient between the measured and the predicted values
of DeepSynergy was 0.73. Applying DeepSynergy for classification of these novel drug combina-
tions resulted in a high predictive performance of an AUC of 0.90. Furthermore, we found
that all compared methods exhibit low predictive performance when extrapolating to unexplored
drugs or cell lines, which we suggest is due to limitations in the size and diversity of the dataset.
We envision that DeepSynergy could be a valuable tool for selecting novel synergistic drug
combinations.
Availability and implementation: DeepSynergy is available via www.bioinf.jku.at/software/Deep
Synergy.
Contact: klambauer@bioinf.jku.at
Supplementary information: Supplementary data are available at Bioinformatics online.
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1 Introduction
Administering drug combinations instead of monotherapy can lead
to an increased efficacy compared to single drug treatments
(Csermely et al., 2013; Jia et al., 2009). Furthermore, host toxicity
and adverse side effects are likely reduced, since doses of drug com-
binations are typically lower than doses of single agents (Chou,
2006; O’Neil et al., 2016). Drug resistance can be decreased or even
overcome through combination therapy (Huang et al., 2016;
Kruijtzer et al., 2002; Tooker et al., 2007). Therefore, drug combi-
nations are investigated across various medical areas, such as cancer
(Al-Lazikani et al., 2012), viral disease including human immunode-
ficiency virus (HIV) and hepatitis C virus infections (Clercq, 2007)
as well as fungal (Chen et al., 2016; Groll and Tragiannidis, 2009)
and bacterial infections (Tamma et al., 2012; Worthington and
Melander, 2013). However, drug combination effects can be adverse
and even lead to shorter progression free survival of cancer patients
(Hecht et al., 2009; Tol et al., 2009). Therefore, finding synergistic
drug pairs for a particular cancer type is important for improving
efficacy of anticancer treatment.
Until recently, effective drug combinations were proposed based
on clinical experience. However, ‘trial-and-error’ is time-, labor-
and cost-intensive. Furthermore, it might expose patients to
unnecessary or even harmful treatment (Day and Siu, 2016; Pang
et al., 2014). Another strategy to identify synergistic drug pairs with-
out harming patients is high-throughput screening (HTS). A large
number of measurements can be produced in reasonable time at low
costs (Bajorath, 2002; Bleicher et al., 2003; White, 2000). HTS
has also been applied to test for synergistic drug combinations
(He et al., 2016). In these screens different concentrations of two
drugs are applied to a cancer cell line. Despite the importance of
cancer cell lines in biomedical research, their ability to accurately
represent the in vivo state is often questioned. The reason is that
even if there is a high genomic correlation between the original
tumour and the derived cancer cell line, it is still far from perfect
(Ferreira et al., 2013). Furthermore, testing the complete combinato-
rial space with HTS is unfeasible (Goswami et al., 2015; Morris
et al., 2016).
Computational methods such as machine learning models offer
the possibility to efficiently explore the large synergistic space.
Accurate predictive models can be generated by leveraging the avail-
able HTS synergy data. Reliable predictions provide guidance for
in vitro and in vivo research. Furthermore, methods developed to
utilize genomic information for their predictions offer the opportu-
nity to apply them also in an in vivo setting. Therefore, these predic-
tive models are a big step towards precision medicine (Bulusu et al.,
2016). Anti-cancer synergy prediction has already been tackled with
a wide variety of approaches. Methods range from systems biology
methods (Feala et al., 2010), kinetic models (Sun et al., 2016),
mixed integer linear programming methods based on the diseased
gene set (Pang et al., 2014), computational methods based on gene
expression profiles after treatment with single drugs and dose
response curves (Goswami et al., 2015; Yang et al., 2015), to
machine learning approaches including Random Forests and Naive
Bayes methods (Li et al., 2015; Wildenhain et al., 2015). However,
these methods are restricted to certain pathways, targets or cell lines,
or require transcriptomic data of cell lines under compound treat-
ment. In contrast, our approach only requires a single transcrip-
tomic characterization of the cell line without compound treatment,
and the chemical structure of the two drugs.
Two crowdsourced challenges were focused on computational
methods for drug combinations. In 2012, a challenge considered
only a single cell line (OCI-LY3) and 14 different drugs (Bansal
et al., 2014). Recently, a second challenge was launched to deter-
mine the state-of-the-art of prediction of synergy scores (Yu, 2016).
The dataset consisted of 3800 synergy score samples of pre-specified
drug combinations. Although the research questions addressed in
these challenges are undoubtedly of high importance, the competi-
tion was grounded on datasets with limited size and did not evaluate
the performance of methods for novel drug combinations.
Due to the fast development of high-throughput methods, the
amount of available synergy data points has tremendously increased.
Publicly available databases such as ASDCD (Chen et al., 2014) con-
taining antifungal combinations and DCDB (Liu et al., 2010, 2014)
with approved and investigational combinations, play a key role in
providing good quality training data for developing computational
predictive methods. A review of these resources has been discussed
in Bulusu et al. (2016). Recently, a large HTS synergy study (O’Neil
et al., 2016) with more than 20 000 synergy measurements was per-
formed, which offers the possibility to evaluate computational meth-
ods for predicting novel drug combinations. The dataset covers 38
drugs and 39 cancer cell lines. Therefore, the performed HTS cov-
ered 83% of the possible two drug combinations. Both experimental
and approved drugs were tested. The used cancer cell lines origi-
nated from seven different tissue types.
Previous methods were developed and optimized for small data-
sets. However, methods developed for limited data might not be
appropriate anymore. Predictive performance can be improved,
since more data is available and methods which learn from tens of
thousands of data points can be used. Deep Neural Networks
(DNNs), which strongly profit from large datasets, have impacted
many scientific disciplines and achieved new state-of-the-art per-
formance (LeCun et al., 2015). Deep Learning has set new records
in image (Farabet et al., 2013; Krizhevsky et al., 2012) and speech
recognition (Hinton et al., 2012; Sainath et al., 2013). Recently,
DNNs also found their way into drug design (Ma et al., 2015; Mayr
et al., 2016). DNNs have the ability to learn abstract representations
from high-dimensional data, which is useful for solving complex
tasks. The difficult process of identifying new drugs includes many
challenges for which Deep Learning is perfectly suited, due to large
amounts of available data and its ability to extract important fea-
tures (Unterthiner et al., 2015).
In this work, we present DeepSynergy, a Deep Learning
approach for predicting the synergy of drug combinations and a
thorough method comparison. The model was designed for regres-
sion, since treating the task as a classification problem might over-
simplify the actual situation (Chen et al., 2016; Pahikkala et al.,
2015). DeepSynergy uses both compound as well as genomic
information as inputs. By incorporating genomic information,
DeepSynergy can learn to distinguish different cancer cell lines and
find specific drug combinations that have maximal efficacy on a
given cell line. DeepSynergy combines information about the cancer
cell line and the drug combination in its hidden layers to form a
combined representation that eventually leads to accurate predic-
tions of drug synergies. DeepSynergy was trained on a large publicly
available synergy dataset (O’Neil et al., 2016). To benchmark the
performance of our approach we compare the results to other state-
of-the-art machine learning methods: Gradient Boosting Machines
(Friedman, 2001), Random Forests (Breiman, 2001), Support
Vector Machines (Cortes and Vapnik, 1995) and Elastic Nets (Zou
and Hastie, 2005). A median polishing method serves as baseline for
the task. Overall, we found that DeepSynergy can predict drug syn-
ergies of novel combinations within the space of explored drugs and
cell lines with high accuracy and significantly outperforms the other
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methods at this task. Furthermore, we investigated the performance
of the methods at extrapolating to drug combinations which include
either novel drugs or novel cell lines and found that these scenarios
are challenging for all methods.
2 Materials and methods
2.1 Dataset
We used a recently published large-scale oncology screen produced
by Merck & Co. (O’Neil et al., 2016) to train our models. The data-
set comprises 23 062 samples, where each sample consists of two
compounds and a cell line. Thereby, the dataset covers 583 distinct
combinations, each tested against 39 human cancer cell lines derived
from 7 different tissue types (see Supplementary Table S1). Pairwise
combinations were constructed from 38 diverse anticancer drugs
(14 experimental and 24 approved, see Supplementary Table S2), of
which 22 were tested exhaustively in combination (the ‘exhaustive’
set), while the remaining 16 (the ‘supplemental’ set) were tested only
in combination with those of the exhaustive set (see Fig. 1d). Each
sample was assayed according to a 4-by-4 dosing regimen in quadru-
ple replicate, measuring the rate of cell growth relative to control
after 48 h. Notably in contrast to previous combination screening
protocols (Griner et al., 2014), separate single agent screens using
eight concentrations with six replicates were performed, rather than
included in the checkerboard; from these, it was possible to define
the edges of the combination surface (where one drug is absent)
by interpolating values sampled from fitted Hill curves, leading to
5-by-5 concentration point surfaces for each of the samples (see
Fig. 1c).
2.1.1 Synergy score
The degree of synergy indicated in a surface is typically quantified
by its deviation from that of one simulated according to a theoretical
model, such as Loewe Additivity (Loewe, 1953), Bliss Independence
(Bliss, 1939), Highest Single Agent (Tan et al., 2012) or the recent
Zero Interaction Potency (Yadav et al., 2015). The original publica-
tion (O’Neil et al., 2016) released only the raw surfaces as
Supplementary Material. Therefore, we calculated Loewe Additivity
values using the batch processing mode of Combenefit (Di Veroli
et al., 2016). At this stage, replicates were averaged resulting in a set
of 22 737 (compound, compound, cell line, synergy value) quartets.
2.1.2 Chemical descriptors and genomic features
To represent the input data in numeric form we used both chemical
information from the drugs, and genomic information capturing dis-
ease biology. After removing salts, the chemical representations
were protonated appropriate for pH 7.4 with OpenBabel (O’Boyle
et al., 2011). Chemical features were then calculated for both drugs
of a drug combination. We calculated three different types of chemi-
cal features. Counts of extended connectivity fingerprints with a
radius of 6 (ECFP_6) (Rogers and Hahn, 2010) were generated with
jCompoundMapper (Hinselmann et al., 2011). Additionally,
ChemoPy (Cao et al., 2013) was used to calculate predefined
physico-chemical properties. The set of chemical features was com-
pleted by binary toxicophore features based on a set of toxicophores
collected from the literature. Toxicophores are substructures which
are known to be toxic (Singh et al., 2016). The chemical feature
space was reduced by filtering out zero variance features. The final
set of chemical features consists of 1309 ECFP_6, 802 physico-
chemical and 2276 toxicophore features.
Fig. 1. Synergy calculation workflow. (a) Single agent screens at 8 concentration points were run for each of the 38 compounds against each of the 39 cell lines.
(b) Checkerboards of 4-by-4 nonzero concentrations were measured for each of the 583 tested combinations, again for each of the cell lines. (c) Values at the
checkerboard concentrations were interpolated from the fitted Hill curves from (a), and combined with the measured checkerboards from (b) to yield a 5-by-5
matrix, from which Loewe synergy values could be obtained. (d) The procedure from (c) was performed for each pairwise combination of the drug pairs. Notably
self–self combinations were not explicitly measured. Furthermore, pairwise combinations within a set of 16 of the drugs (the ‘supplemental’ set) were similarly
not measured (hence the gray block in the bottom right of the heatmap). This procedure was repeated for each cell line to yield a 38  38  39 data cube of input
data, from which training, validation and test data were drawn using stratified nested cross-validation
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The cell lines were described by their gene expression profile.
The profiles of the untreated cells were downloaded from the
ArrayExpress database (accession number: E-MTAB-3610) (Iorio
et al., 2016). The measurements were performed on an Affymetrix
Human Genome U219 array plate. The raw data was quantile
normalized and summarized with Factor Analysis for Robust
Microarray Summarization (FARMS) (Hochreiter et al., 2006).
FARMS additionally provides Informative/Non-Informative calls
for each gene (Talloen et al., 2007), which were used to filter the
gene expression data to a final set of 3984 genomic features.
2.2 Deep learning
DeepSynergy is a feed forward neural network, which maps input
vectors representing samples to a single output value, the synergy
score. The samples are described by concatenated vectors which
include the features of two drugs and one cell line. In Figure 2, the
basic setup of DeepSynergy is illustrated. The neurons in the input
layer receive the gene expression values of the cell line and chemical
descriptors of both drugs as inputs. The information is then propa-
gated through the layers of the DeepSynergy network until the out-
put unit that produces the predicted synergy score. Since the
network should not differentiate between the drug combination AB
presented in the ordering A-B or B-A, we double the measurements
by presenting each sample twice in the training set. Once the drug
features are used in an A-B and once in a B-A order. For prediction
both ways of sample representation are propagated through the net-
work and averaged. We observed that DeepSynergy learns to predict
the same value for drug combination AB in the order A-B and B-A.
We considered different hyperparameter settings, namely different
data normalization strategies, in combination with conic or rectangu-
lar layers both with different numbers of neurons. Furthermore, we
investigated different learning rates as well as regularization techni-
ques. The considered hyperparameter space is summarized in Table 1
and described in more detail in the following.
For data normalization we employed three different types of input
normalization: (i) standardizing all inputs to zero mean and unit var-
iance, (ii) standarizing and applying hyperbolic tangent and (iii) stand-
ardizing, hyperbolic tangent and standardizing again. The hidden
layers apply rectified linear activations (Nair and Hinton, 2010), and
the output layer used a linear activation. The mean squared error was
the objective function which was minimized. We considered two or
three hidden layers with 2048, 4096 and 8192 neurons in the first hid-
den layer. We tested rectangular layers, that have a constant number
of neurons in each hidden layer, and conic layers, in which the num-
ber of units halves in each hidden layer. We used stochastic gradient
descent with learning rates of 102, 103, 104 and 105 as optimizer
and early-stopping and dropout as regularization techniques. For
early-stopping, the adequate number of training iterations was deter-
mined by a moving average over 25 epochs on a validation set. For
dropout, we either used a dropout rate of 0.2 and 0.5 for the input
and the hidden layers, respectively, or no dropout at all. The best
hyperparameters were determined using grid search.
2.3 Method comparison
We compared DeepSynergy to a baseline method and four state-of-
the-art machine learning methods that we adapted to this task. The
three different normalization techniques described in the previous
section were considered for each method. Furthermore, all methods
were allowed to adjust their hyperparameters with grid search. The
full range of tested hyperparameters can be found in the
Supplementary Material. For all methods their implementation in
scikit-learn (Pedregosa et al., 2011) was used.
• Median Polish. A median polish model serves as baseline for this
task. Since we are not aiming at predicting novel drugs it is possi-
ble to make a new prediction based on the median of the two
drugs and the cell line involved in the combination. The synergy
score is estimated by averaging over the medians of the two drugs
and the cell line median.
• Elastic nets. Elastic nets (Zou and Hastie, 2005) were used to
compare DeepSynergy with a linear method. During hyperpara-
meter selection we considered different values for a and the L1
ratio. Supplementary Table S3 summarizes the considered hyper-
parameter ranges for Elastic Nets.
• Support Vector Machines (SVMs). We use a modified version of the
MinMax kernel to handle three types of features, binary, counts
and continuous ones, simultaneously. This kernel outperformed the
Tanimoto and the RBF kernel in previous tasks (Mayr et al., 2016).
It is not in the standard implementation of scikit-learn, therefore it
was necessary to precompute the similarity of two molecules. The








where N(p, x) quantifies feature p for compound x, and P are the
considered features. The kernel matrix is calculated from the pre-
processed data, which is then split into a positive and negative
Fig. 2. Schematic illustration of our Deep Learning approach. The input con-
sists of three parts: the chemical descriptors for drug A and drug B, and the
genomic information of the cell line. The inputs are propagated through the
network to the linear output unit. The thereby obtained result is the predicted
synergy value. The best performing architecture was determined via explora-
tion of different hyperparameters which are listed in Table 1
Table 1. Hyperparameter settings considered for DeepSynergy
Hyperparameter Values considered
Preprocessing norm; normþtanh; normþtanhþnorm
Hidden units [8192, 8192]; [4096, 4096]; [2048, 2048];
[8192, 4096]; [4096, 2048]; [4096, 4096, 4096];
[2048, 2048, 2048]; [4096, 2048, 1024];
[8192, 4096, 2048]
Learning rates 102; 103; 104; 105
Dropout no dropout; input: 0.2, hidden: 0.5
Note: All possible combinations of the presented hyperparameters were
optimized via grid-search.
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part since the kernel function can only be applied to positive val-
ues. We used a -Support Vector Machine for regression and
tuned the hyper parameters  and C. Supplementary Table S4
summarizes the considered hyperparameter ranges for SVMs.
• Random Forests. We considered different numbers of estimators
(trees) and tuned the number of features considered in each split.
Supplementary Table S5 summarizes the considered hyperpara-
meters for Random Forests.
• Gradient Boosting Machines. We trained a Gradient Boosting
Machine for regression with different numbers of trees, numbers
of features considered in each split and different learning rates.
Supplementary Table S6 summarizes the considered hyperpara-
meter ranges for Gradient Boosting Machine.
2.4 Stratified nested cross-validation
In order to benchmark the performance of DeepSynergy with the
competing methods we used stratified nested cross validation.
Figure 3 illustrates different cross validation strategies. In contrast
to random cross validation, the test samples are not distributed ran-
domly across folds. We used a stratified cross validation approach,
where the test sets were selected to leave out drug combinations (see
Fig. 3 second column). We used a 5-fold nested cross validation set-
ting (Baumann and Baumann, 2014), in which the hyperparameters
are selected in an inner loop based on the validation error. The best
performing model of the inner loop was then assessed on an outer
test fold to obtain a performance estimate unbiased by hyperpara-
meter selection. Furthermore, we performed stratified cross valida-
tion to determine the generalization ability of methods for novel




Figure 4 displays the density distribution of the synergy scores based
on the Loewe model. The values range from 326 to 179. The
median and the standard deviation of the distribution are 4.37 and
22.89, respectively. By definition all synergy scores above zero are
synergistic. However, drug combinations exhibiting a highly syner-
gistic effect are attractive candidates for clinical studies. Therefore,
we focused on the top 10%. Synergistic combinations with a meas-
ured score higher than 30 were classified as positive. In the negative
class antagonistic, additive and low synergistic drug combinations
were summarized.
3.2 Method comparison
The methods were compared based on their ability to predict syn-
ergy values of novel drug combinations. The primary metric is
the mean squared error (MSE), for which the models were optimized
for during training. Additionally, we report the mean root mean
squared error (RMSE) and the mean Pearson correlation coefficient
of each method. Table 2 summarizes the performance of the differ-
ent methods based on the MSE, RMSE and Pearson correlation coef-
ficient for left out drug combinations respectively.
DeepSynergy achieved a test MSE of 255, while Gradient
Boosting Machines and Random Forests attained only inferior per-
formance of 275 and 308, respectively. Support Vector Machines
and Elastic Nets performed similar with MSEs of 398 and 420,
respectively, while median polish, which was used as a baseline,
achieved the worst result with an MSE of 478. The relative improve-
ment of the best performing method to the baseline is 53%.
A Wilcoxon signed rank-sum test was used to determine if the differ-
ences in the mean squared errors are significant and all the P-values
are below 0.05. Hence, DeepSynergy outperforms the other machine
learning methods significantly with regard to MSE, RMSE and
Pearson correlation.
Additionally, we evaluated the performance on novel drugs and
novel cell lines. The predictive performance of all methods both on
novel drugs and novel cell lines is considerably worse than on novel
drug combinations. Across methods, the MSEs for the prediction of
novel drugs range between 414 and 500, and the MSEs for the pre-
diction of novel cell lines range between 387 and 461 (see
Supplementary Section S4). Therefore, the best performing method
shows only a relative improvement of 16 and 17% compared to the
baseline method that neither uses compound nor cell line features.
We hypothesize that the low predictive performance arises from the
low number of training examples in terms of chemical compounds
(38 examples) and cell lines (39 examples). Therefore, synergy data-
sets with larger numbers of chemical compounds and cell lines could
represent a large boost for predictive synergy models.
Fig. 3. Different cross validation strategies. Random cross validation is shown
in the first column. Three different stratified cross validation strategies are
shown in the following columns. White and orange squares indicate train set
and test set samples, respectively (Color version of this figure is available at
Bioinformatics online.)
Fig. 4. Density plot displaying the distribution of the synergy scores. On the
x-axis the synergy scores calculated with Combenefit are shown. On the
y-axis the density is displayed. Most of the values are close to zero, i.e. addi-
tive. High values indicate highly synergistic combinations, whereas combina-
tions with low values exhibit only subadditive effects
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3.3 Performance metrics
RMSE, MSE depend on the dataset and are therefore difficult to
compare across different datasets. To further characterize the pre-
dictive performance of DeepSynergy and to give comparable meas-
ures, we also provide performance measures that are typical for
classification tasks: area under the receiver operator characteristics
curve (ROC AUC), area under the precision recall curve (PR AUC),
accuracy (ACC), balanced accuracy (BACC), precision (PREC), sen-
sitivity (TPR), specificity (TNR) and Cohen’s Kappa. In Table 3 all
performance measures are summarized. When we consider this task
as binary classification task with a synergy value threshold of 30,
our approach achieves a mean ROC AUC and ROC PR of 0.90 and
0.56, respectively. Since in the training data a lot of additive combi-
nations (i.e. synergy score around 0) are present, the model tends to
make more conservative predictions. Therefore, it is important to
choose an appropriate threshold for binarising the predicted synergy
scores. The threshold for predictions of DeepSynergy was optimized
for balanced accuracy on the validation set. With this procedure to
select the threshold, DeepSynergy exhibits an ACC, BACC, PREC,
TPR, TNR and Kappa of 0.92, 0.76, 0.56, 0.57, 0.95 and 0.51,
respectively.
3.4 Comparison with previous studies
Our predicted synergy scores agree with observations in previous
studies, examples of which are as follows. Kano et al. conducted
experiments to evaluate the response of cell line PA-1 to combina-
tions including Paclitaxel. They reported additive effects for
Paclitaxel in combination with SN-38 (Kano et al., 1998a),
Vinorelbine (Kano et al., 1999b), 5-FU (Kano et al., 1996),
Doxorubicin (Akutsu et al., 1995). Our predictions agree with those
previous findings, given that the absolute value of the predicted syn-
ergy scores is low (with values of 1.48, 13.0, 0.12 and 10.2,
respectively). Furthermore, Paclitaxel was combined with Etopside
(Kano et al., 1999a) and Methotrexate (Kano et al., 1998b), result-
ing in additive/antagonistic effects, which agree with our predictions
of synergy values of -19.75 and -23.42, respectively. Furthermore,
two other experimental studies focused on Irinotecan of which SN-
38 is the active metabolite. In a combination with 5-FU on HT-29
an additive effect was observed (Guichard et al., 1997), which
agrees with our prediction of 0.57 for 5-FU and SN-38 on HT-29.
Furthermore, they investigated the combination Irinotecan with
Oxaliplatin on HT-29, HCT-116 and SW-620 (Guichard et al.,
2001). The highest effects were observed for HCT-116, whereas
SW-620 showed the lowest response. Our predictions for the cell
lines HCT-116, HT-29 and SW-620 are 5.82, 1.72 and 0.90 and
therefore agree with the experimentally discovered order. Thus, our
predictions are confirmed by previous investigations of the respec-
tive drug combinations.
3.5 DeepSynergy architecture
The architecture of DeepSynergy was determined by the hyperpara-
meter selection procedure, whose results are given in Supplementary
Table S7. This procedure identified that tanh normalization,
comprising first standardization and then a hyperbolic tangent fol-
lowed by a second standardization, performed best. Furthermore,
DeepSynergy has conic layers. A possible explanation for the fact
that conic layers perform well, is their regularizing effect. The lower
number of parameters available in the higher layers, which forces
the model to generalize by constructing only the most important rep-
resentations of chemical properties of the input compound combina-
tion. Additionally, a large number of units in the first layer (8192)
performed better. A smaller learning rate (105) and dropout regula-
rization were also essential for learning performant networks.
Overall, DeepSynergy has a conic architecture with two hidden
layers having 8192 neurons in the first and 4096 in the second hid-
den layer. It uses tanh input normalization, has a learning rate of
105, an input dropout rate of 0.2 and a hidden layer dropout rate
of 0.5.
3.6 Applicability domain
Furthermore, we analyzed performance of DeepSynergy across cell
lines and drugs by determining the respective Pearson correlation
Table 2. Methods comparison based on mean squared error (MSE) with corresponding confidence intervals and P-values, mean root mean
squared error (RMSE) as well as mean Pearson correlation coefficient over the five test folds
Method MSE Confidence Interval P-value RMSE Pearson’s r
Deep Neural Networks 255.49 [239.93, 271.06] 15.91 6 1.56 0.736 0.04
Gradient Boosting Machines 275.39 [258.24, 292.54] 9.6  1017 16.54 6 1.37 0.696 0.02
Random Forests 307.56 [286.83, 328.29] 1.2  1073 17.49 6 1.63 0.656 0.03
Support Vector Machines 398.39 [371.22, 425.56] <10280 19.92 6 1.28 0.506 0.03
Elastic Nets 420.24 [393.11, 447.38] <10280 20.46 6 1.29 0.446 0.03
Baseline (Median Polish) 477.77 [448.68, 506.85] <10280 21.80 6 1.49 0.436 0.02
Table 3. Performance metrics for the classification task
Performance Metric ROC AUC PR AUC ACC BACC PREC TPR TNR Kappa
Deep Neural Networks 0.90 6 0.03 0.596 0.06 0.92 6 0.03 0.766 0.03 0.56 6 0.11 0.576 0.09 0.95 6 0.03 0.516 0.04
Gradient Boosting Machines 0.89 6 0.02 0.596 0.04 0.87 6 0.01 0.806 0.03 0.38 6 0.04 0.716 0.05 0.89 6 0.01 0.436 0.03
Random Forests 0.87 6 0.02 0.556 0.04 0.92 6 0.01 0.736 0.04 0.57 6 0.04 0.496 0.08 0.96 6 0.01 0.486 0.04
Support Vector Machines 0.81 6 0.04 0.426 0.08 0.76 6 0.06 0.736 0.03 0.23 6 0.04 0.696 0.08 0.77 6 0.07 0.246 0.05
Elastic Nets 0.78 6 0.04 0.346 0.10 0.75 6 0.05 0.716 0.02 0.21 6 0.03 0.656 0.07 0.76 6 0.06 0.226 0.03
Baseline (Median Polish) 0.77 6 0.04 0.326 0.09 0.76 6 0.04 0.706 0.03 0.22 6 0.03 0.626 0.06 0.78 6 0.04 0.226 0.04
Note: All values are mean values6 one standard deviation. The best and second best performance is shown in bold and italic, respectively. The columns pro-
vide the performance measures area under ROC curve (ROC AUC), area under precision-recall curve (PR AUC), accuracy (ACC), balanced accuracy (BACC),
precision (PREC), sensitivity (TPR), specificity (TNR) and Kappa.
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coefficients. Figure 5 displays the results per (a) drugs and (b) cell
lines on the left and right side, respectively.
Correlation coefficients for the set of drugs analyzed range from
0.57 to 0.84. Predicted values for five drugs exhibit a correlation
coefficient below 0.6 and 39% of the drugs can be predicted with a
correlation coefficient higher than 0.7. On the left side of Figure 5
no clear association between targets and correlation can be
observed. Therefore, target specific mechanisms do not explain the
performance differences. Furthermore, the performance is not
affected by the number of drugs acting on the same target.
Correlation coefficients of the set of cell lines analyzed range
from 0.56 to 0.84. Only two cell lines exhibit a correlation below
0.6. More than 50% of the cell lines can be predicted with a correla-
tion higher than 0.7. On the right side of Figure 5 no association can
be observed between tissue type and correlation. Nor can perform-
ance differences be explained by the number of cell lines originating
from a specific tissue type.
We checked whether these performance differences arise from
(a) different number of training data points, (b) different quality of
synergy scores and (c) different distributions of the synergy scores
(see Supplementary Figs S4 and S5), (d) tissue/target specific mecha-
nisms (see Fig. 5a) and (e) tissue/target coverage in the dataset (see
Fig. 5b). Neither of these effects showed a clear association with per-
formance. Therefore, we believe that these differences arise (f) from
the fact that some biological mechanisms can be modelled better
than others. This could be connected to the measurements that we
can obtain from cell lines and whether they are able to capture these
biological processes. Investigating (f) would require further lab
experiments, which is out of scope for this work.
4 Availability
We implemented DeepSynergy as a publicly available web-service.
The predictions of DeepSynergy are put into context of the training
data to improve interpretability of the results. The web-service is
available via www.bioinf.jku.at/software/DeepSynergy.
5 Discussion
We have developed a novel Deep Learning based method,
DeepSynergy, that predicts synergy scores of drug combinations for can-
cer cell lines with high accuracy. The method requires cancer cell lines
to be described by their genomic profiles, and the compounds to be rep-
resented by their chemical descriptors. We have demonstrated that
DeepSynergy is able to provide best predictions in a cross-validation set-
ting with external test sets, outperforming other methods by a wide
margin. Prioritizing drug combinations on the basis of the predictions
of DeepSynergy at an AUC of 0.90, could already decrease the time and
costs spent on experimental validation (Simm et al., 2018). Since the
dataset has only a limited number of different drugs and cell lines all
methods show difficulties to generalize well across novel drugs and cell
lines. Nonetheless, we are convinced that this limitation can be over-
come soon, since dataset sizes increased rapidly over the past years and
we expect this trend to continue also in the future. With increased data-
set sizes, we presume that our approach can be extended to other areas,
in which drug combinations play and important role, for example to
antifungals (Chen et al., 2014) and antibiotics (Tamma et al., 2012).
With respect to predictive performance, both increased dataset size and
algorithmic advances (Klambauer et al., 2017) could further improve
DeepSynergy. Overall, our findings suggest that DeepSynergy could be
a valuable tool for selecting novel synergistic drug combinations.
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